CoChat

A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial

Open access
Heyland, Daren K., van Zanten, Arthur R. H., Grau-Carmona, Teodoro, Evans, David, Beishuizen, Albertus, Schouten, Jeroen, Hoiting, Oscar, Bordejé, Maria Luisa, Krell, Kenneth, Klein, David J., Gonzalez, Jesus, Perez, Aitor, Brown, Randy, James, Joyce, Harris, M. Scott, the Investigators of the PROMOTE LP101-CL-201 Trial, Heyland, Daren K., Evans, David C., Jolley, Sarah, Raines, Ronald, Krell, Kenneth, Falls, Idaho, Grau-Carmona, Teodoro, Serviá-Goixart, Lluis, Perez-Quesada, Sonia, Herrero-Meseguer, Jose Ignacio, Calvo-Herranz, Enrique, Lorencio, Carol, Peredes, Amparo, Yébenes-Reyes, Juan Carlos, Garcia-Martinez, Miguel Angel, Cervera, Manuel, Bordejé, Maria Luisa, Fernadez-Ortega, Juan Franscisco, Fernández-González, Inmaculada, van Zanten, Arthur, Beishuizen, Albertus, Schouten, Jeroen, Hoiting, Oscar, Wilhelmina, Canisius, Stelfox, Tom, Posadas, Juan · 2019 · Intensive Care Medicine
Cited by 41

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

PurposeEnteral feeding intolerance (EFI) is a frequent problem in the intensive care unit (ICU), but current prokinetic agents have uncertain efficacy and safety profiles. The current study compared the efficacy and safety of ulimorelin, a ghrelin agonist, with metoclopramide in the treatment of EFI.MethodsOne hundred twenty ICU patients were randomized 1:1 to ulimorelin or metoclopramide for 5 days. EFI was diagnosed by a gastric residual volume (GRV) ≥ 500 ml. A volume-based feeding protocol was employed, and enteral formulas were standardized. The primary end point was the percentage daily protein prescription (%DPP) received by patients over 5 days of treatment. Secondary end points included feeding success, defined as 80% DPP; gastric emptying, assessed by paracetamol absorption; incidences of recurrent intolerance (GRV ≥ 500 ml); vomiting or regurgitation; aspiration, defined by positive tracheal aspirates for pepsin; and pulmonary infection.ResultsOne hundred twenty patients were randomized and received the study drug (ulimorelin 62, metoclopramide 58). Mean APACHE II and SOFA scores were 21.6 and 8.6, and 63.3% of patients had medical reasons for ICU admission. Ulimorelin and metoclopramide resulted in comparable %DPPs over 5 days of treatment (median [Q1, Q3]: 82.9% [38.4%, 100.2%] and 82.3% [65.6%, 100.2%], respectively, p = 0.49). Five-day rates of feeding success were 67.7% and 70.6% when terminations unrelated to feeding were excluded, and there were no differences in any secondary outcomes or adverse events between the two groups.ConclusionsBoth prokinetic agents achieved similar rates of feeding success, and no safety differences between the two treatment groups were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00134-019-05593-2

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 41

Metadata

Authors
Heyland, D. K., van Zanten, A. R. H., Grau-Carmona, T., Evans, D., Beishuizen, A., Schouten, J., Hoiting, O., Bordejé, M. L., Krell, K., Klein, D. J., Gonzalez, J., Perez, A., Brown, R., James, J., Harris, M. S., the Investigators of the PROMOTE LP101-CL-201 Trial, Heyland, D. K., Evans, D. C., Jolley, S., Raines, R., Krell, K., Falls, I., Grau-Carmona, T., Serviá-Goixart, L., Perez-Quesada, S., Herrero-Meseguer, J. I., Calvo-Herranz, E., Lorencio, C., Peredes, A., Yébenes-Reyes, J. C., Garcia-Martinez, M. A., Cervera, M., Bordejé, M. L., Fernadez-Ortega, J. F., Fernández-González, I., van Zanten, A., Beishuizen, A., Schouten, J., Hoiting, O., Wilhelmina, C., Stelfox, T., & Posadas, J.
Venue
Intensive Care Medicine
Published
2019-05-01
Volume
45
Issue
5
Pages
647-656
ISSN
  • 0342-4642 (ISSN-L)
  • 1432-1238
OpenAlex
W2943965773
Cited by
41
References
11
FWCI
4.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial. https://app.cochat.ai/papers/10.1007/s00134-019-05593-2
The paper
Heyland, D. K., van Zanten, A. R. H., Grau-Carmona, T., Evans, D., Beishuizen, A., Schouten, J., Hoiting, O., Bordejé, M. L., Krell, K., Klein, D. J., Gonzalez, J., Perez, A., Brown, R., James, J., Harris, M. S., the Investigators of the PROMOTE LP101-CL-201 Trial, Heyland, D. K., Evans, D. C., Jolley, S., . . . Posadas, J. (2019). A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-019-05593-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.